Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACRS Aclaris Therapeutics

Market Closed 01-16 16:00:00 EST

2.62

-0.05

-1.87%

盘后2.63

+0.01+0.37%

19:49 EST

High2.69	Low2.61	Vol765.91K
Open2.69	D1 Closing2.67	Amplitude3.00%
Mkt Cap283.86M	Tradable Cap190.35M	Total Shares108.35M
T/O2.02M	T/O Rate1.05%	Tradable Shares72.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":2.62,"timestamp":1768597200000,"preClose":2.67,"halted":0,"volume":765910,"hourTrading":{"tag":"盘后","latestPrice":2.6297,"preClose":2.62,"latestTime":"19:49 EST","volume":5856,"amount":15365.32,"timestamp":1768610994491},"delay":0,"floatShares":72651442,"shares":108345239,"eps":-1.3076717,"marketStatus":"Market Closed","change":-0.05,"latestTime":"01-16 16:00:00 EST","open":2.69,"high":2.69,"low":2.61,"amount":2023774.71574,"amplitude":0.029963,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.3076717,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1444190400000,"exchange":"NASDAQ","adjPreClose":2.67,"preHourTrading":{"tag":"盘前","latestPrice":2.68,"preClose":2.67,"latestTime":"09:29 EST","volume":355,"amount":956.190015,"timestamp":1768573799511},"postHourTrading":{"tag":"盘后","latestPrice":2.6297,"preClose":2.62,"latestTime":"19:49 EST","volume":5856,"amount":15365.32,"timestamp":1768610994491},"volumeRatio":1.1906864318447856,"impliedVol":1.4254,"impliedVolPercentile":0.6175},"requestUrl":"/m/hq/s/ACRS","defaultTab":"news","newsList":[{"id":"2602511043","title":"Aclaris Therapeutics Launches Phase 1b Trial of Bispecific Antibody ATI-052 in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2602511043","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602511043?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:55","pubTimestamp":1768218929,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc. has announced the initiation of a placebo-controlled Phase 1b proof-of-concept trial for ATI-052, its investigational bispecific anti-TSLP/IL-4Rα antibody, in patients with moderate-to-severe atopic dermatitis. The trial will assess the safety, tolerability, and clinical efficacy of ATI-052, as well as pharmacokinetic and pharmacodynamic endpoints. Additionally, Aclaris plans to begin a Phase 1b proof-of-concept trial for ATI-052 in asthma within the first quarter of 2026. Top line results from both trials are expected to be presented in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNews","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL338vJb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4112","BK4585","LU2210149790.SGD","SG9999014021.USD","BK4588","SG9999014013.SGD","BK4007","IE00B64PRP62.GBP","LU2210150020.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","ACRS","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD"],"gpt_icon":0},{"id":"2602511095","title":"Aclaris Therapeutics Initiates Phase 1B Proof-of-Concept Trial in Atopic Dermatitis (Ad) With Its Novel Bispecific Antibody ATI-052","url":"https://stock-news.laohu8.com/highlight/detail?id=2602511095","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602511095?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:55","pubTimestamp":1768218900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7CSW1B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2602511091","title":"Aclaris Therapeutics Inc - Top Line Results From Poc Trials Expected in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602511091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602511091?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:55","pubTimestamp":1768218900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7CSW1B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2602110995","title":"Aclaris Therapeutics Inc - to Initiate Phase 1B Trial in Asthma This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2602110995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602110995?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:55","pubTimestamp":1768218900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7CSW1B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2601817333","title":"BUZZ-U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=2601817333","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601817333?lang=en_us&edition=fundamental","pubTime":"2026-01-07 02:50","pubTimestamp":1767725435,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, TeslaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL6N3Y70M5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUV","VST","COP","EXE","REGN","LYFT","PNC","ACRS","FGBI","EQIX","EPAM","CRNX","WMB","BAC","FIX","IFF","STAA","NBP","CNX","IMSR","NEM","ACN","SG","CFG","APGE","EAT","TPG","NTRS","UAL","JXN","AIG","ALB","ANGO","AEVA","UAA","OS","VRTX","PUMP","TFC","BALL"],"gpt_icon":1},{"id":"2601819813","title":"BUZZ-U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin","url":"https://stock-news.laohu8.com/highlight/detail?id=2601819813","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601819813?lang=en_us&edition=fundamental","pubTime":"2026-01-06 23:52","pubTimestamp":1767714720,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed MartinEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL6N3Y70VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRS","ALMS","ACN","AIG","SHAK","STT","ACRS","NEM","AEVA","VRTX","CDE","MCHP","ALB","APGE","O","CFG","JXN","STAA","REGN","CORZ","GNPX","ALKS","IFF","INTU","OS","NBP","GL","PNC","CRNX","UAA","HL","EPAM","BALL","LMT","VST","TFC","BAC","DLR","ANGO","EQIX","FERG","BK","GILD","ZETA","IMSR"],"gpt_icon":1},{"id":"2601180648","title":"BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2601180648","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601180648?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:12","pubTimestamp":1767708743,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridgeEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL6N3Y70M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JXN","OS","APGE","AIG","ALB","NVIW.SI","VRTX","REGN","NVD2.UK","AU","NVDY","STT","VST","MCHP","VERX","ANGO","FERG","NVDX","BK","IFF","NEM","ALKS","CDE","NTRS","INTU","NBP","ZETA","O","AEVA","NVD3.UK","RTO.UK","ALMS","BALL","HGT.UK","NVDS.UK","HL","NVDU","GL","GNPX","UAA","GILD","ACRS","ACN","NVDS","CRNX"],"gpt_icon":1},{"id":"2601937897","title":"Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2601937897","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601937897?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:02","pubTimestamp":1767704534,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics  said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.Shares of the company were up 3.4% in recent Tuesday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATI","IE00B7SZL793.SGD","IE00B66KJ199.SGD","IE00B19Z4B17.USD","IE0031619046.USD","BK4006","ACRS","LU2065731478.USD","BK4187","BK4007","LU1878469433.USD"],"gpt_icon":0},{"id":"2601544892","title":"BUZZ-Aclaris rises as inflammation drug shows promise in early trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601544892","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601544892?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:31","pubTimestamp":1767702689,"startTime":"0","endTime":"0","summary":"BUZZ-Aclaris rises as inflammation drug shows promise in early trial** Shares of drug developer Aclaris Therapeutics ACRS.O rise 2.3% to $2.71 premarket** Co says its experimental drug ATI-052 showed promising safety and effectiveness in an early-stage clinical trial** ATI-052 aims to treat atopic dermatitis, or eczema, and asthma by blocking inflammation signals - ACRS** Co says drug was well tolerated, with mild side effects such as temporary redness at injection site** ATI-052 stayed in body for 26 days, and may allow dosing once every three months - ACRS** Co plans proof-of-concept trials early this year; larger mid-stage trial in second half of 2026** As of last close, ACRS up ~44% over the past year","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4N3Y70RD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2601917888","title":"Aclaris Therapeutics Inc: Expects Top Line Data From Both Trials in Second Half of 2026.","url":"https://stock-news.laohu8.com/highlight/detail?id=2601917888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601917888?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:59","pubTimestamp":1767700740,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2QKXZK:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2601891206","title":"Aclaris Therapeutics Inc - to Initiate Phase 1B Poc Trials in Ad and Asthma in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601891206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601891206?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:59","pubTimestamp":1767700740,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2QKXZK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2601208891","title":"Aclaris Therapeutics Inc - Phase 2B Trial of ATI-052 in Ad Expected to Initiate in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601208891","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601208891?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:59","pubTimestamp":1767700740,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2QKXZK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2601204891","title":"Aclaris Therapeutics Inc - ATI-052 Well Tolerated With Favorable Safety Profile up to 720 Mg","url":"https://stock-news.laohu8.com/highlight/detail?id=2601204891","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601204891?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:59","pubTimestamp":1767700740,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2QKXZK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2601891757","title":"Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2601891757","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601891757?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:59","pubTimestamp":1767700740,"startTime":"0","endTime":"0","summary":"- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - - Trial Results Support Potential for Exten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213432/37216/en/Aclaris-Therapeutics-Announces-Positive-Interim-Results-of-Phase-1a-Trial-of-Anti-TSLP-IL-4R%CE%B1-Bispecific-Antibody-ATI-052-Supporting-Expedited-Clinical-Development.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","IE00B66KJ199.SGD","ATI","BK4007","IE0031619046.USD","BK4132","LU1169589451.USD","BK4187","LU1878469433.USD","PK","IE00B7SZL793.SGD","ACRS","PD","LU1169590202.USD","BK4006","BK4023","BK4181","IE00B19Z4B17.USD","AD","TSLP","LU2065731478.USD"],"gpt_icon":0},{"id":"2592197719","title":"Aclaris Therapeutics Included in Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2592197719","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592197719?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:16","pubTimestamp":1766178962,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (ACRS) said late Friday it was included in the Nasdaq Biotechnology Index, effective immediately.The index is evaluated yearly and is calculated under a modified capitalization-weighted methodology.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACRS","BK4007","NQmain"],"gpt_icon":0},{"id":"2592971831","title":"Aclaris Therapeutics Joins Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2592971831","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592971831?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:01","pubTimestamp":1766178069,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc. will be added to the Nasdaq Biotechnology Index , effective December 19, 2025. The addition follows the annual evaluation of the index, which requires companies to meet criteria such as minimum market capitalization and average daily trading volume.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL5d36pQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014005.SGD","BK4007","BK4588","IE00B3QW5Z07.USD","BK4585","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","ACRS","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","LU2210150020.SGD"],"gpt_icon":0},{"id":"2586278432","title":"Aclaris Therapeutics management to meet with Cantor","url":"https://stock-news.laohu8.com/highlight/detail?id=2586278432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586278432?lang=en_us&edition=fundamental","pubTime":"2025-11-28 03:35","pubTimestamp":1764272107,"startTime":"0","endTime":"0","summary":"Group Dinner Meeting to be held in New York on December 1 at 6 pm hosted by Cantor. Published first on TheFly – the ultimate source for real-time, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-management-to-meet-with-cantor-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-management-to-meet-with-cantor-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2584267829","title":"Aclaris Therapeutics Q3 Net Income USD -14.614 Million Vs. IBES Estimate USD -15.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584267829","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584267829?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:52","pubTimestamp":1763571139,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Aclaris Therapeutics Q3 revenue USD 3.299 million vs. IBES estimate USD 1.59 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202511:59:46.573 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2J3cl5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2581725067","title":"Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $3.299M Beat $1.405M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581725067","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581725067?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:24","pubTimestamp":1762431898,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 9.09 percent decrease over losses of $(0.11) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48682834/aclaris-therapeutics-q3-eps-0-12-beats-0-14-estimate-sales-3-299m-beat-1-405m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0},{"id":"2581218062","title":"Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2581218062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581218062?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:07","pubTimestamp":1762430862,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Q3 revenue beats estimates, net loss narrowsOverviewAclaris Q3 revenue beats analyst expectations despite a year-over-year declineNet loss for Q3 smaller than expected, reflecting","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0JM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":-0.0076},{"period":"1month","weight":-0.1353},{"period":"3month","weight":0.3789},{"period":"6month","weight":0.6273},{"period":"1year","weight":0.0438},{"period":"ytd","weight":-0.1296}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":0.118663},{"month":2,"riseRate":0.4,"avgChangeRate":-0.024357},{"month":3,"riseRate":0.4,"avgChangeRate":-0.054834},{"month":4,"riseRate":0.4,"avgChangeRate":-0.010072},{"month":5,"riseRate":0.5,"avgChangeRate":-0.043272},{"month":6,"riseRate":0.6,"avgChangeRate":-0.004956},{"month":7,"riseRate":0.6,"avgChangeRate":0.009999},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019617},{"month":9,"riseRate":0.4,"avgChangeRate":0.026634},{"month":10,"riseRate":0.4,"avgChangeRate":0.132278},{"month":11,"riseRate":0.363636,"avgChangeRate":0.075295},{"month":12,"riseRate":0.727273,"avgChangeRate":0.092435}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction